Dendritic cell vaccines: A review of recent developments and their potential pediatric application

References

• Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64:83-103; PMID:24488779
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Sayour EJ, Reap E, Schmittling R, DeLeon G, Norberg P, Desjardins A, Friedman AH, Friedman HS, Archer G, et al. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol research 2015; 3:320-5; PMID:25387895; http://dx.doi.org/10.1158/2326-6066.CIR-14-0100
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother 2015; 64:1251-60; PMID:26105625; http://dx.doi.org/10.1007/s00262-015-1731-3
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediat Blood Cancer 2010; 54:519-25; PMID:19852061
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, Downie P, Hassall TE, Tang ML, Ashley DM. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 2004; 6:236-46; PMID:15279716; http://dx.doi.org/10.1215/S1152851703000668
   PubMed Web of Science ®Google Scholar
• Lasky JL, 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013; 33:2047-56; PMID:23645755
   PubMed Web of Science ®Google Scholar
• Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, Felzmann T. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 2007; 9:755-70; PMID:17917887; http://dx.doi.org/10.1080/14653240701589221
   PubMed Web of Science ®Google Scholar
• Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet (London, England) 2000; 356:1163-5; PMID:11030299; http://dx.doi.org/10.1016/S0140-6736(00)02762-8
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-9; PMID:11731436
   PubMed Web of Science ®Google Scholar
• Himoudi N, Wallace R, Parsley KL, Gilmour K, Barrie AU, Howe K, Dong R, Sebire NJ, Michalski A, Thrasher AJ, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 2012; 14:271-9; PMID:22484634; http://dx.doi.org/10.1007/s12094-012-0795-1
   PubMed Web of Science ®Google Scholar
• Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediat Hematol Oncol 2002; 24:220-3; PMID:11990310; http://dx.doi.org/10.1097/00043426-200203000-00012
   PubMed Web of Science ®Google Scholar
• Shilyansky J, Jacobs P, Doffek K, Sugg SL. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J Pediat Surgery 2007; 42:54-61; discussion; PMID:17208541; http://dx.doi.org/10.1016/j.jpedsurg.2006.09.008
   PubMed Web of Science ®Google Scholar
• Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediat Transplant 2009; 13:746-53; PMID:19067917; http://dx.doi.org/10.1111/j.1399-3046.2008.01066.x
   PubMed Web of Science ®Google Scholar
• Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, Ancelet LR, Mester B, Sharples KJ, Findlay MP, Hamilton DA, et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neuro-Oncol 2015; 121:319-29; PMID:25366363; http://dx.doi.org/10.1007/s11060-014-1635-7
   PubMed Web of Science ®Google Scholar
• Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K, Tanaka M, Sakashita K, Kobayashi T, Kurata T, et al. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature. Cytotherapy 2015; 17:330-5; PMID:25484308; http://dx.doi.org/10.1016/j.jcyt.2014.10.003
   PubMed Web of Science ®Google Scholar
• Nair SK, Driscoll T, Boczkowski D, Schmittling R, Reynolds R, Johnson LA, Grant G, Fuchs H, Bigner DD, Sampson JH, et al. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. J Neuro-oncol 2015; 125:65-74; PMID:26311248; http://dx.doi.org/10.1007/s11060-015-1890-2
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Hoogerbrugge PM, de Rakt MW, Aarntzen EH, Figdor CG, Adema GJ, de Vries IJ. Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediat Blood Cancer 2007; 49:924-7; PMID:17486645; http://dx.doi.org/10.1002/pbc.21246
   PubMed Web of Science ®Google Scholar
• Vakkila J, Vettenranta K, Sariola H, Saarinen-Pihkala UM. Poor yield of dendritic cell precursors from untreated pediatric cancer. J Hematother Stem Cell Res 2001; 10:787-93; PMID:11798505; http://dx.doi.org/10.1089/152581601317210881
   PubMedGoogle Scholar
• Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T, Takamatsu K, Haga E, Koba C, Nishimura Y, Senju S. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013; 20:504-13; PMID:22875043; http://dx.doi.org/10.1038/gt.2012.59
   PubMed Web of Science ®Google Scholar
• Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, Duenzl M, Feinstein B, Cherry J, Waller EK. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004; 10:848-57; PMID:15570253; http://dx.doi.org/10.1016/j.bbmt.2004.07.008
   PubMed Web of Science ®Google Scholar
• Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95:2484-90; PMID:10753825
   PubMed Web of Science ®Google Scholar
• Zeng J, Wu C, Wang S. Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. Sci Rep 2015; 5:15262; PMID:26471005; http://dx.doi.org/10.1038/srep15262
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Ojima T, Nakamori M, Nakamura M, Hayata K, Katsuda M, Iida T, Miyazawa M, Iwahashi M, Yamaue H. [Cancer vaccine therapy using genetically modified induced pluripotent stem cell-derived dendritic cells expressing the TAA gene]. Gan To kagaku Ryoho Cancer Chemother 2013; 40:1575-7; PMID:24393853
   PubMedGoogle Scholar
• Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Ikuta Y, Ikeda T, Kageshita T, Ihn H, Nishimura Y, et al. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother 2009; 32:219-31; PMID:19242378; http://dx.doi.org/10.1097/CJI.0b013e318194b63b
   PubMed Web of Science ®Google Scholar
• Zeng J, Wang S. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cell Transl Med 2014; 3:69-80; PMID:24292792; http://dx.doi.org/10.5966/sctm.2013-0070
   PubMed Web of Science ®Google Scholar
• de Haar C, Plantinga M, Blokland NJ, van Til NP, Flinsenberg TW, Van Tendeloo VF, Smits EL, Boon L, Spel L, Boes M, et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology 2015; 4:e1023973; PMID:26451309; http://dx.doi.org/10.1080/2162402X.2015.1023973
   PubMed Web of Science ®Google Scholar
• Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123:989-97; PMID:26252465; http://dx.doi.org/10.3171/2015.1.JNS141554
   PubMed Web of Science ®Google Scholar
• Collignon A, Perles-Barbacaru AT, Robert S, Silvy F, Martinez E, Crenon I, Germain S, Garcia S, Viola A, Lombardo D, et al. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget 2015; 6:23462-79; PMID:26405163; http://dx.doi.org/10.18632/oncotarget.4359
   PubMed Web of Science ®Google Scholar
• Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther 2016; 7:133-8; PMID:26855819; http://dx.doi.org/10.4292/wjgpt.v7.i1.133
   PubMedGoogle Scholar
• Nguyen ST, Nguyen HL, Pham VQ, Nguyen GT, Tran CD, Phan NK, Pham PV. Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations. Onco Targets Ther 2015; 8:323-34; PMID:25674007
   PubMed Web of Science ®Google Scholar
• Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015; 111:862-7; PMID:25873455; http://dx.doi.org/10.1002/jso.23897
   PubMed Web of Science ®Google Scholar
• Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Saeboe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 2015; 64:381-8; PMID:25548092; http://dx.doi.org/10.1007/s00262-014-1642-8
   PubMed Web of Science ®Google Scholar
• Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer 2014; 2:4; PMID:24829761; http://dx.doi.org/10.1186/2051-1426-2-4
   PubMedGoogle Scholar
• Kabelitz D, Medzhitov R. Innate immunity–cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007; 19:1-3; PMID:17157490; http://dx.doi.org/10.1016/j.coi.2006.11.018
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16:27-34; PMID:14751761; http://dx.doi.org/10.1016/j.smim.2003.10.004
   PubMed Web of Science ®Google Scholar
• Shen HTB, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 2008; 181:1849-58; PMID:18641322; http://dx.doi.org/10.4049/jimmunol.181.3.1849
   PubMed Web of Science ®Google Scholar
• Napolitani G RA, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunol 2005; 6:769-76; PMID:15995707; http://dx.doi.org/10.1038/ni1223
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Tsitsilonis OE. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. Immunotherapy 2013; 5:497-511; PMID:23638745; http://dx.doi.org/10.2217/imt.13.24
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58:1-14; PMID:18719915; http://dx.doi.org/10.1007/s00262-008-0568-4
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. Clin Cancer Res 2012; 18:6497-508; PMID:23032745; http://dx.doi.org/10.1158/1078-0432.CCR-12-2189
   PubMed Web of Science ®Google Scholar
• Matthews KCN, Klasse PJ, Moutaftsi M, Carter D, Salazar AM, Reed SG, Sanders RW, Moore JP. Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PLoS One 2013; 8:e63785; PMID:23700434
   PubMed Web of Science ®Google Scholar
• Pollack IF JR, Butterfield LH, Okada H. Peptide vaccine therapy for childhood gliomas. Neurosurgery 2013; 60:113-9; PMID:23839362; http://dx.doi.org/10.1227/01.neu.0000430769.33467.68
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With a-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744
   PubMed Web of Science ®Google Scholar
• Chang WT, Lai TH, Chyan YJ, Yin SY, Chen YH, Wei WC, Yang NS. Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. PloS One 2015; 10:e0122374; PMID:25825910; http://dx.doi.org/10.1371/journal.pone.0122374
   PubMed Web of Science ®Google Scholar
• Lin CC, Pan IH, Li YR, Pan YG, Lin MK, Lu YH, Wu HC, Chu CL. The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines. PloS One 2015; 10:e0116191; PMID:25723174; http://dx.doi.org/10.1371/journal.pone.0116191
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma X, Su C, Peng B, Du J, Jia H, Luo M, Fang C, Wei Y. Uric acid enhances the antitumor immunity of dendritic cell-based vaccine. Sci Rep 2015; 5:16427; PMID:26553557; http://dx.doi.org/10.1038/srep16427
   PubMed Web of Science ®Google Scholar
• Seth A, Heo MB, Sung MH, Lim YT. Infection-mimicking poly(gamma-glutamic acid) as adjuvant material for effective anti-tumor immune response. Int J Biol Macromol 2015; 75:495-504; PMID:25709015; http://dx.doi.org/10.1016/j.ijbiomac.2015.02.013
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9; PMID:25762141; http://dx.doi.org/10.1038/nature14320
   PubMed Web of Science ®Google Scholar
• Kang TH, Kim YS, Kim S, Yang B, Lee JJ, Lee HJ, Lee J, Jung ID, Han HD, Lee SH, et al. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget 2015; 6:27751-62; PMID:26336989; http://dx.doi.org/10.18632/oncotarget.4859
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033-43; PMID:22159452; http://dx.doi.org/10.1007/s00262-011-1176-2
   PubMed Web of Science ®Google Scholar
• Benteyn D, Van Nuffel AM, Wilgenhof S, Bonehill A. Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules. Methods Mol Biol 2014; 1139:3-15; PMID:24619665; http://dx.doi.org/10.1007/978-1-4939-0345-0_1
   PubMedGoogle Scholar
• Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci 2015; 106:1659-68; PMID:26395101; http://dx.doi.org/10.1111/cas.12824
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863
   PubMed Web of Science ®Google Scholar
• Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett 2013; 336:253-9; PMID:23523609; http://dx.doi.org/10.1016/j.canlet.2013.03.010
   PubMed Web of Science ®Google Scholar
• van der Waart AB, Fredrix H, van der Voort R, Schaap N, Hobo W, Dolstra H. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother 2015; 64:645-54; PMID:25724840; http://dx.doi.org/10.1007/s00262-015-1668-6
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Y, Liu J, Shao S, Li X, Gao J, Niu H, Wang X. Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. Onco Targets Ther 2014; 7:1389-96; PMID:25120371; http://dx.doi.org/10.2147/OTT.S65367
   PubMed Web of Science ®Google Scholar
• Rossowska J, Anger N, Kicielinska J, Pajtasz-Piasecka E, Bielawska-Pohl A, Wojas-Turek J, Dus D. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology 2015; 220:389-98; PMID:25454807; http://dx.doi.org/10.1016/j.imbio.2014.10.009
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; http://dx.doi.org/10.1038/nri1668
   PubMed Web of Science ®Google Scholar
• Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, Young JW. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114:555-63; PMID:19465693; http://dx.doi.org/10.1182/blood-2008-11-191197
   PubMed Web of Science ®Google Scholar
• Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012; 41:765-97; PMID:23017145; http://dx.doi.org/10.3109/08820139.2012.689405
   PubMed Web of Science ®Google Scholar
• Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
   PubMed Web of Science ®Google Scholar
• Narita Y, Kitamura H, Wakita D, Sumida K, Masuko K, Terada S, Nakano K, Nishimura T. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 2013; 190:812-20; PMID:23248265; http://dx.doi.org/10.4049/jimmunol.1103797
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Ocadlikova D, Lemoli RM, Curti A. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res 2015; 2015:253191; PMID:25815345
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
   PubMed Web of Science ®Google Scholar
• Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:24734217; http://dx.doi.org/10.4161/onci.27589
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 2013; 31:2460-8; PMID:23715577; http://dx.doi.org/10.1200/JCO.2012.46.8280
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Miyagawa N, Mitsui K, Matsuoka M, Kojima Y, Takahashi H, Ootsubo K, Nagai J, Ueno H, Ishibashi T, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediat Blood Cancer 2015; 62:1058-60; PMID:25400122; http://dx.doi.org/10.1002/pbc.25327
   PubMed Web of Science ®Google Scholar
• Wu KH, Wu HP, Weng T, Peng CT, Chao YH. Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy. Curr Oncol 2015; 22:303-6; PMID:26300669; http://dx.doi.org/10.3747/co.22.2719
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 2016; 22:1364-70; PMID:26534966; http://dx.doi.org/10.1158/1078-0432.CCR-15-0491
   PubMed Web of Science ®Google Scholar
• Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, Furst DE. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford, England) 2016; 55:669-79; PMID:26628580; http://dx.doi.org/10.1093/rheumatology/kev382
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 2015; PMID:26644233
   PubMedGoogle Scholar